Drug Pricing Program Reporting Requirements

Drug Pricing Program Reporting Requirements

340B Reporting Req

Drug Pricing Program Reporting Requirements

OMB: 0915-0176

Document [rtf]
Download: rtf | pdf

Drug Pricing Program Reporting Requirements


Process for audits:


1. A manufacturer must notify the entity in writing when it believes a violation of Section 340B of the Public Health Service (PHS) Act has occurred.


2. The manufacturer must submit an audit work plan describing the audit to the Office of Pharmacy Affairs for review. The work plan will be reviewed for reasonable purpose, scope, and a determination that only those records of the covered entity that directly pertain to the potential violation will be accessed.


3. The manufacturer must submit the audit report to the Office of Pharmacy Affairs and informational copies to the Office of Inspector General and the PHS Office of Audit Services. The audit report must be prepared in accordance with the reporting standards for performance audits in Government Auditing Standards, Current Revision.


4. The covered entity must provide a written response to the audit report.



Process for formal dispute resolution:


1. The participating manufacturer or covered entity requesting the dispute resolution must submit a written request to the Office of Pharmacy Affairs. Upon receipt of the request for a review, the chairperson of the review committee will send a letter to the party alleged to have committed a violation. The letter will include: a) the name of the party making the allegation; b) the allegation; c) documentation supporting the party's position, and; 4) a request for a response to or rebuttal of the allegation within 30 days.


2. The party alleged to have committed a section 340 violation is required to provide a written response or rebuttal.


3. The review committee, chaired by a representative from the Office of Pharmacy Affairs, shall review all documentation submitted by the disputing parties and made a determination. The review committee shall prepare a written document containing the findings and detailed response supporting the proposed decision. The written decision will be sent with a transmittal letter to both parties.



Public Burden Statement: An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. The OMB control number for this project is 0915‑0176. Public reporting burden for this collection of information is estimated to average 4 hours for the audit process and 13 hours for the dispute resolution for the time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 10-33, Rockville, Maryland, 20857.


File Typetext/rtf
File TitleDrug Pricing Program Reporting Requirements
AuthorHrsa
Last Modified ByHrsa
File Modified2009-12-28
File Created2009-12-28

© 2024 OMB.report | Privacy Policy